KLRA news

Latest 2 stories · newest Sep 11, 2026

KLRA

Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’

Markets Sep 11, 2026 sentiment 0.00 Source: benzinga.com ↗

KLRA

Kailera reports Q1 2026 results, initiates Phase 3 ribupatide trials

Clinical-stage biotech Kailera advanced its obesity pipeline with five late-stage trial initiations and positive data from partner programs, reporting cash runway into mid-2028. The company's ribupatide franchise and diverse drug candidates position it competitively in the obesity treatment market.

Earnings May 26, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same KLRA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/KLRA/newsSTART FREE